What this means
This paper is a review of earlier research on aged cells and cancer. It says these cells may either slow or speed up tumour growth.
Plain-English summary written by an AI model from the abstract. The original is below.
- Who it was tested in
- A review of earlier studies
- Kind of research
- A summary of earlier studies
The science
- Original title
- The Molecular Landscape of the Senescence-EMT Interplay: Deciphering Tumour Plasticity Through Molecular Signatures and Multi-Omic Profiling.
- Authors
- Verdugo-Sivianes EM, Campos-Silva C, García-Márquez JL et al.
- Journal
- Cancers
- Published
- Oct 16, 2026
- Study type
- Review
- PMID
- 42882898 ↗
Abstract
Therapy-induced senescence (TIS) is a common response to anticancer treatments, characterised by stable cell cycle arrest and the acquisition of a complex senescence-associated secretory phenotype (SASP). Initially regarded as a beneficial mechanism that limits tumour growth, growing evidence indicates that TIS is a highly dynamic and heterogeneous process with context-dependent effects that can either suppress or promote tumour progression. The SASP is a central mediator of tumour plasticity, linking TIS to epithelial-to-mesenchymal transition (EMT), cancer stemness, microenvironmental remodelling, therapeutic resistance, and metastatic dissemination. These findings highlight the therapeutic potential of senotherapeutic approaches, including senolytic and senomorphic agents, as key components of one-two-punch therapeutic strategies to selectively eliminate or modulate persistent senescent cells and improve treatment outcomes. Recent advances in multi-omics technologies, artificial intelligence, and liquid biopsy are further transforming the study of senescence by enabling comprehensive molecular characterisation, biomarker discovery, patient stratification, and real-time monitoring of tumour evolution. Collectively, current evidence supports a paradigm shift in which senescence should be considered a dynamic regulator of tumour plasticity and a promising target for precision oncology strategies.
Verdugo-Sivianes EM, Campos-Silva C, García-Márquez JL et al. The Molecular Landscape of the Senescence-EMT Interplay: Deciphering Tumour Plasticity Through Molecular Signatures and Multi-Omic Profiling. Cancers. 2026. doi:10.3390/cancers18193204. PMID: 42882898. https://pubmed.ncbi.nlm.nih.gov/42882898/
Related research
New fluorescent sensor detects cells aging from cancer and lung drugs
Researchers built a glowing probe that lights up only in certain aged cells. It may help scientists track these cells in living animals, but this is early lab work.
Mixing a senescence-clearing drug with trametinib slowed glioma regrowth in mice
Researchers found a drug combination that cleared aging-like tumour cells in mice and slowed regrowth. This does not show the combination would work the same way in children.
A vaccine-style treatment in mice eased diabetes signs and aged cell markers
Mice given a treatment aimed at a virus-like gene showed less weight gain and better blood sugar control. This study was in mice and cells, so it does not show the same would happen in people.
Aging cells that support stem cells may disrupt them through chemical signals
This is a review that pulls together older and newer studies. It proposes a model, but it does not show that the model is true.
Cx43 protein may boost breast cancer drug response in lab tests
Researchers studied a protein called Cx43 that helps cells talk to each other. They found it may help a breast cancer drug slow tumor growth. This early work is not yet checked by other scientists, so it does not show this would help people.
A new vaccine clears aging cells in mice and may extend lifespan
Researchers made a vaccine aimed at old, worn-out cells called senescent cells. In mice, it cleared some of these cells and helped metabolism. This is early work, so it does not show the vaccine would help people.
See all research on Senolytics →